Thinking that a delay in a companies previously cited ' on track' process will entice big pharma to try and look at purchasing it more cheaply is A+ grade copium.
Acquisition etc simply don't work like that.
To be picked up, you need to produce results. usually phase 3 results.
To produce results, you need product.
PAT-DX1 is delayed for a phase 1 trial due to this manufacturing delay.
Yes, I'm aware that DX3 is what many consider to be the big ticket item, but trying to spin a manufacturing delay as a positive for any potential bigger company sniffing around is just foolish.
